In point of fact, Sunitinib (Sutent, SU11248) and Sorafinib (Nexavar, BAY43-9006), two multi-targeted PTK inhibitors, have shown significant clinical benefits in cancer therapy and approved for the treatment of advanced renal cell carcinoma (RCC) [10], [11], [12], [13]. This evidence concerns the gene PTK2B and cancer.